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The Need To Revise discouNT RaTes iN BelgiuM, The NeTheRlaNds, 
PolaNd aNd The uk
O’Mahony JF1, Paulden M2
1Trinity College Dublin, Dublin, Ireland, 2University of Alberta, Edmonton, AB, Canada
Objectives: To demonstrate the need to revise discount rates in the cost-effective-
ness analysis (CEA) methods guidelines in Belgium, the Netherlands, Poland and 
the UK. MethOds: We identify what discount rates are recommended in the CEA 
guidelines of the countries above and examine what rationale has been provided 
in each case. We assess the recommended guidelines in the context of the current 
theory and empirical evidence on discounting. Results: The UK requires discount-
ing of 3.5% for cost and effects in its basecase guidance, but also recommends 1.5% 
for public health interventions and for specific life-saving interventions. No ade-
quate justification has been provided for this disparity. Applying different discount 
rates for the same goal of achieving health gain from the same pool of resources is 
illogical and yields inefficient outcomes. Belgium, the Netherlands and Poland all 
recommend differential discounting of costs and effects. The discounting guidance 
in these countries pre-dates recent work that further clarifies the basis for differ-
ential discounting. This is significant, as this recent work shows how, under certain 
assumptions, the differential between costs and effects can be linked to growth in 
threshold. In turn, this may imply that the differential employed in these countries 
may be too great. Finally, assuming that the discount rate applied to costs should 
approximate government borrowing costs, it is likely that the cost discount rate is 
too high in the base case of all of the countries considered here. cOnclusiOns: 
The choice of discount rates is important as they are highly influential on the cost-
effectiveness of many interventions. Applying different discount rates to different 
interventions is not justified. Similarly, the rates applied in countries recommend-
ing differential discounting lack firm justification. Resource allocation in all the 
countries considered would likely be improved by the application of a lower com-
mon discount rate.
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Objectives: The clinical value of genomic tests is not always apparent, and very 
few have demonstrated cost-effectiveness. The objective of this conceptual paper 
is to understand whether the principles and methods of cost-effectiveness analy-
sis (CEA) are appropriate for the evaluation of genomic-based diagnostic tests, 
such as whole genome sequencing. MethOds: Literature on CEA methods to 
evaluate genomic tests was systematically searched using ‘pearl growing’ meth-
ods. Data were extracted to identify challenges and solutions to conducting CEA in 
this context. The key characteristics of genomic tests from an economic perspec-
tive were summarized and used to distinguish further challenges. Results: Our 
review highlights two main differences between CEA of genomic tests and that 
of other technologies: the complexities of evaluating tests for multiple disorders 
and the potential for genomic information to have consequences for future gen-
erations requiring infinite time horizons. Another common feature, not unique 
to genomic-based diagnostic tests but commonly identified in the literature, was 
the valuation of non-health benefits. Alternatives to evaluate the diagnosis of 
multiple disorders are discussed: an iterative approach assessing each diagnosis 
independently; an aggregate approach combining the cost and benefits from all 
disorders into a single evaluation; a pragmatic approach that identifies the most 
important disorders combined with a qualitative assessment of the direction of 
bias for disorders not included in the full analysis. Consideration of the potential 
for infinite time horizons suggests CEA should focus on systems that could store, 
and share, genomic information between generations. cOnclusiOns: The chal-
lenges shared with other health technologies, particularly diagnostic tests, suggest 
that the general principles and methods of CEA are appropriate for genomic tests. 
Further methodological research would be valuable on approaches for assess-
ing the value of sharing genomic information across generations, approaches 
to evaluate tests for multiple disorders and trading-off health and non-health 
benefits.
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Standard cost-effectiveness methods and critical appraisal toolkits may not be ade-
quate for complex interventions. We systematically reviewed and quality assessed 
cost-effectiveness studies of a complex intervention, propose a series of new ques-
tions to inform their critical appraisal and discuss how future research should be 
targeted to improve the methods. Reablement was used as an example of a complex 
intervention. Reablement is a multidisciplinary and multifactorial intervention to 
support people to relearn activities of daily living. The systematic review identi-
fied 12 cost-effectiveness studies on reablement, out of 3,311 unique records. The 
12 included studies were data extracted and quality evaluated using a standard 
checklist. No study provided enough information to inform the decision on whether 
reablement is cost-effective and should be reimbursed by the payer. The issues 
included: (i) the use of a perspective not relevant for the decision-maker, (ii) lack of 
consideration for inter-sectoral effects, (iii) short time horizon, (iv) poor descriptive 
detail on the interventions, (v) limited comparators, (vi) poor quality evidence on 
effectiveness, (vii) limited evaluation of uncertainty and (viii) no consideration of the 
panel hearings. In two recent highly publicised Food and Drug Administration advi-
sory panel recommendations for orkambi (cystic fibrosis; Vertex Pharmaceuticals) 
and flibanserin (hypoactive sexual desire disorder; Sprout Pharmaceuticals), tes-
timonials from patients involved in the trials appeared to play an important role 
in influencing positive recommendations. Feedback from patients participating 
in clinical trials can provide important information on the potential benefits of a 
drug beyond the clinical endpoints measured in a trial. However, critics suggest 
that the purposively selected patient testimonials used within these regulatory 
interactions are not sufficiently robust sources of data. The authors argue that 
patient testimonials which influence regulatory decision making should be con-
sidered as qualitative data and therefore appraised in-line with other qualitative 
data submitted as part of a new drug application e.g., qualitative data supporting 
content validity of patient-reported outcome measures. Testimonials are unlikely 
to be considered either credible or rigorous in their current format, particularly as 
samples are often heavily biased towards patients who have experienced positive 
outcomes whilst on the product. Patient interviews planned a priori can provide 
valuable insights on the efficacy of a new medication and other important factors 
such as tolerability and adherence. The authors propose a structured framework to 
eliciting and analysing these data through qualitative interviews ‘nested’ within 
clinical trials. The authors present a procedural checklist for ensuring that cred-
ible and robust data are collected. This includes ensuring representative sampling 
(e.g., patients on both treatment arms and with varying socio-demographic and 
clinical profiles), utilising trained qualitative interviewers experienced in quali-
tative data collection and analysis, and timing of interviews (e.g., during and/or 
after the clinical study).
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Objectives: Phase III trials typically exclude patients with certain baseline character-
istics, such as older age or co-morbidities, and thereby hamper learning of new drugs’ 
effectiveness in real-life. A simulation study was conducted to support implementa-
tion of new inclusion criteria for Phase 3 trials in schizophrenia without increasing 
sample size nor compromising detection of the new drug effect. MethOds: A simula-
tion study was performed examining the impact of re-introducing through stratifying 
by each of the following excluded patients population: age > 65 years, duration of 
illness < 3 years, patients with previous suicide attempts, patients with history of 
alcohol or substance abuse, and patients treated in private practices. Patients with 
these characteristics were multiplied in a synthetic trial population until their real-life 
proportion in schizophrenia was reached. The simulation used data subsets from the 
10,281-patient observational SOHO cohort study. A “base case RCT” was created by 
applying typical Phase 3 exclusion criteria. A series of “synthetic RCTs” were defined 
by replacing patients with SOHO patients that were initially excluded. The real-life 
drug effect was predicted from each synthetic RCT through regression models and 
compared with the real-life effect in SOHO. Results: Perhaps surprisingly, effects of 
all 3 investigated drugs were found to be larger in real-life than in the base case RCT. 
Synthetic RCTs were created by replacing patients of the base RCT with patients with 
a given baseline characteristic. Prediction of real-life effects improved with increasing 
replacement in terms of mean squared prediction errors and coverage of confidence 
interval. However, the impact of introducing these “real-life” populations was not 
equal among factors. For instance, introducing older patients minimally improved 
prediction of real-life effects, while allowing inclusion of just 5% of patients with 
past suicide attempts (who make up 25% of the real-life schizophrenia population) 
significantly improved effectiveness predictions.
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iN NeTWoRk MeTa aNalysis
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Objectives: Develop a method to quickly test whether a network meta-analysis 
evidence network is connected. BACKGROUND Network meta-analysis, or mixed 
treatment comparisons, is a method to combine evidence on multiple treatments 
that have been compared in randomised controlled trials that form a connected 
network of treatment comparisons. Evidence networks consist of nodes, repre-
senting treatments, and edges, representing clinical trials comparing two treat-
ments. If nodes corresponding to treatments are not connected, they cannot be 
compared. Connectedness is typically tested by visual inspection, however this 
is time consuming when there are many separate networks representing dif-
ferent outcomes, subgroups, and scenarios, and also prone to error, especially 
in large networks . Path finding algorithms can be used to automate testing for 
connectedness, but these are slow and inefficient. We present a fast and sim-
ple approach to test connectedness. MethOds: Our method constructs a sym-
metric square matrix, called the direct connection matrix, with the number of 
rows and columns equal to the number of treatments in the network. We fill 
this matrix with ones where treatments of the corresponding row and column 
have been compared in a trial, and zeros otherwise. The diagonal is filled with 
ones. Exponentiation of the matrix to the number of treatments, minus one, 
gives the indirect connection matrix. Non-zero entries of this final matrix rep-
resent treatment combinations that can be compared using available evidence, 
and vice versa. This test is easy to implement in software and can be conducted 
rapidly. We prove the validity of the method mathematically and illustrate with 
application to a network of anticoagulants for the prevention of stroke in atrial 
fibrillation. cOnclusiOns: We have developed a simple and rapid test of con-
nectedness of networks that is easy to automate and can be applied to any network 
meta-analysis.
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products among internal and/or external stakeholders, despite increasing use of 
PRO tools in regulatory studies 3) Maintenance of motivation and understanding 
of the study procedures in relevant healthcare professionals throughout the study 
period Key elements for best practices would include: 1) Strategize recruitment 
of physicians depending on their environment and resources available: general 
practitioners vs. hospital physicians 2) Deepen the understanding of the value of 
PRO assessments and contents of PRO questionnaires among internal/external 
stakeholders 3) Reinforce cross-functional collaboration in order to accelerate site 
recruitment, patient enrollment and the return of patient surveys We will further 
discuss the above difficulties during the planning and implementation phases of 
PMS with a PRO survey, as well as best practices based on our experience so far in 
Japan. These considerations and experiences will highlight important implications 
in conducting a PRO survey in PMS as a valuable opportunity to obtain real-world 
patient-relevant data in elderly patients immediately after a new product is avail-
able in the market.
PRM260
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Objective: Gaining adequate market access and reimbursement can be particu-
larly challenging for orphan drugs. Barriers include inadequate real world data 
on the disease’s epidemiology and its burden of illness. We deployed a unique 
combination of methodologies used in a multi-layered observational data capture 
approach to collect de-identified, publication-worthy clinical and resource utiliza-
tion data in a probability sample of patients with a rare disease (pulmonary non-
tuberculosis mycobacteria [PNTM]). We combine a new methodology (“blinded 
physician proportion survey”) with a new use of an old methodology (Delphi expert 
survey). MethOds: First-round studies in France, Germany, Italy, Spain, and the 
United Kingdom consisted of a “blinded physician specialty proportion” survey to 
determine the probability of physician selection by specialty (2,585 participating 
physicians), a nationally representative chart review with participating physi-
cians to determine target patients by region (619 physicians – 1,429 patients) and a 
Delphi study (an anonymous collaborative estimating methodology completed by 
six internationally recognized PNTM experts) to gain consensus on annual preva-
lence of PNTM for each target country. A second-round of survey and use of the 
collaborative estimating process is currently being completed consisting of a chart 
review with physicians of a nationally representative sample (n= 30 per country) 
in a treatment refractory sub-group of PNTM patients to capture country specific 
treatment patterns and disease-related costs. “Refractory” is defined as at least 
one post-diagnostic positive culture despite 6 months of treatment. Results: We 
developed a rigorous methodology to identify a sub-group population to address the 
gap of actual disease prevalence by country. Publication reviewers have consistently 
and congruently confirmed the first-round epidemiologic study methodology met 
their respective required scientific standards. cOnclusiOns: Observational chart 
surveys in rare diseases that obtain a probability sample, a requirement for sample 
validity, can be used to provide essential disease-related metrics to populate market 
access and reimbursement evaluation procedures.
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a coNcePTual seaRch filTeR To ideNTify Real-WoRld evideNce
Ogden K1, Thompson JC2, Halfpenny NJ2, Scott DA3
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Objectives: Systematic reviewers utilise filters to focus searches of electronic 
databases to identify specific study designs. Established, tested search filters are 
available from groups which regularly conduct reviews such as the Cochrane 
Group, SIGN and CADATH. Although studies in the real-world are not new, novel 
phrases such as real-world evidence (RWE) are increasingly used to identify obser-
vational studies. Currently available search filters for observational and non-
randomised studies do not adequately capture newer terms used. We have thus 
developed a method to identify frequently used MeSH terms in RWE studies and 
a search filter to include these terms. MethOds: A PubMed (MEDLINE®) search 
for RWE stated in the title/abstract was conducted. Articles with “real-world” and 
either “data”, “evidence” or “research” in the title or abstract were selected; Case 
Reports, Comment, Editorial, Letter, News were removed. MeSH terms associated 
with articles were analysed and frequency counted; those relating to study design 
or outcome reporting were chosen for inclusion in the search filter. Results: 
The MEDLINE® search identified 179 studies reporting RW and either data, evi-
dence or research in the title. Of the 179, 151 were publication types of interest. 
The most frequently used MeSH terms related to RWE identified were ‘Treatment 
Outcome’ (n= 30), ‘Evidence-based Medicine’ (n= 17), ‘Retrospective Studies’ (n= 15), 
‘Databases, Factual’ (n= 14), and ‘Time Factors’ (both n= 14). A search strategy was 
developed combining MeSH and free-text terms to identify RWE. cOnclusiOns: 
For every systematic review it is important to validate searches to ensure they are 
retrieving relevant studies; as new terminologies such as RWE are introduced to 
describe study design, reviewers need to adapt search filters. The method proposed 
allows searches to be adapted as terminologies are introduced and become more 
established.
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MeThodological guideliNes foR ecoNoMic dRug evaluaTioN sTudies 
iN PoRTugal: MajoR gaPs aNd NeW ToPics iN The sTudies evaluaTed 
BeTWeeN 2010 aNd 2014
Ramos R, Gonçalves L, Caldeira S, Fernandes C, Teixeira M
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opportunity cost. These issues informed the development of a new checklist, which 
was subsequently applied. Critical appraisals of cost-effectiveness studies should 
consider the aforementioned issues to conclude on their quality and potential to 
inform decision-making. More research is needed how to quantify the opportunity 
costs of complex interventions, particularly when multiple sectors are affected.
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Health authorities may face a variety of options when deciding upon expanding 
their national pediatric immunization programs, ranging between an ad-hoc vac-
cine selection versus a targeted multi-year program to achieve efficiency goals. The 
vaccine portfolio management model allows the comparison of these two options 
over a fixed period of time. This optimization model is based on disease burden, vac-
cine impact and associated costs which are balanced against available vaccination 
budget and pre-defined public health priorities. Potential targets consist of reduc-
tion in disease events, or GP visits, or hospital occupancy rates, or deaths, or disease 
management cost. The model determines the optimal combination of vaccines 
selected per year, resulting in achieving the targeted public health outcome at the 
lowest annual budget. The financial results are then compared with those obtained 
after an ad-hoc selection of vaccines. The model was adapted for Japan in children 
up to 5 years old considering vaccines against pneumococcal disease, rotavirus, 
mumps and influenza disease based on published data. As an exemplary objective 
function we selected the reduction in hospital occupancy rates by 35% over a 5-year 
period. The portfolio model indicates that the optimal strategy consists of vacci-
nation against rotavirus, influenza, and mumps at 90% coverage and 55% vaccine 
coverage against pneumococcal disease, requiring an annual budget of 331 million 
EUR. In case of a lower budget, the vaccine selection would prioritize first rotavirus, 
followed by influenza, then mumps and pneumococcal vaccine (depending on the 
available budget) to reduce hospital occupancy rates to a maximum extent. With 
an ad-hoc selection of vaccine introduction, the budget required to achieve the 
same objective function may increase by more than10% each year compared with 
the previous approach. A vaccine portfolio management model can therefore sup-
port decision makers in making efficient choices when expanding their national 
pediatric immunization programs.
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bAckgROund: A health economic model was developed to compare treatment 
strategies for uterine fibroids (UF). Bleeding and pain were identified as the prin-
ciple disease-related symptoms affecting quality of life. Clinical trial data meas-
ured bleeding and pain through the pictorial bleeding assessment chart (PBAC) and 
visual analogue scale (VAS), respectively. However, the impact of PBAC and VAS on 
a single index measure of quality of life (QOL) is not widely studied. Objectives: 
Develop a symptom-driven utility function for patients with symptomatic UF, link-
ing incremental changes in PBAC and VAS to a single index measure of QOL that 
enables the calculation of quality-adjusted life-years (QALYs). MethOds: PBAC, 
VAS, and EQ-5D levels based on clinical trial data were used in the analysis. Two 
ordinary least squares regressions (Reg1 and Reg2) were conducted with EQ-5D 
(UK value set) as the dependent variable. Reg1 (N= 965) included PBAC and VAS 
as linear and quadratic terms to account for both linear and non-linear relation-
ships. Reg2 (N= 962) used a wider specification of independent variables including 
all regressors in Reg1 plus demographics and physical characteristics. Results: 
The regression coefficients from Reg1 were -0.0001 (p< 0.01) and -0.0044 (p< 0.01) 
for a one-unit change in the linear components of PBAC and VAS respectively, an 
intercept of 0.9164, and adjusted R2 of 0.3135. The quadratic coefficient estimates 
were very small, positive, and not statistically significant. An increase in the linear 
components of PBAC (VAS) of 300 (30) results in a 0.0355 (0.1308) unit decrease 
in EQ-5D QALY-weight. Differences in the coefficients of PBAC and VAS on EQ-5D 
between Reg1 and Reg2 were small. cOnclusiOns: The method described shows 
a pragmatic way to estimate QALY-weights in a health economic model that is 
responsive to incremental changes in patient symptoms for any intervention where 
PBAC and VAS data is available.
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assessMeNT iN PosT-MaRkeTiNg suRveillaNce foR diseases iN The 
eldeRly
Akiyama S1, Watanabe Fujinuma E1, Rossi B2, Aitoku Y2, Adachi K1
1Bayer Yakuhin, Ltd., Tokyo, Japan, 2Bayer Yakuhin, Ltd., Osaka, Japan
Growing attention has been paid to patient-centric approach in clinical practice. 
The assessment of patient-reported outcomes (PROs) encourages communication 
between patients and physicians about goals of care. Post-marketing surveillance 
(PMS) is one of the available opportunities to collect large-scale, real-world data on 
patients’ experiences and PROs. Since PROs must be answered by patients them-
selves by definition, elderly patients may face specific challenges and need extra 
support to conduct a PRO survey as part of PMS. Various difficulties in conducting 
a PRO survey in PMS are expected, such as: 1) Additional support required at the 
participating sites for elderly patients. For example, they may need someone to read 
out the questions or record the responses for them without influencing patients’ 
responses 2) Lack of understanding of the value of PRO assessments for marketed 
